Editors' ChoiceCancer

Patient-derived organoids: Are PDOs the new PDX?

See allHide authors and affiliations

Science Translational Medicine  25 Jul 2018:
Vol. 10, Issue 451, eaau7377
DOI: 10.1126/scitranslmed.aau7377

Abstract

Patient-derived organoids in pancreatic cancer maintain genotypic, transcriptomic, and potentially phenotypic responses to chemotherapy of the primary tumor.

View Full Text